Moderna, Inc. (NASDAQ:MRNA) Shares Sold by Summit Investment Advisors Inc.

Summit Investment Advisors Inc. decreased its position in shares of Moderna, Inc. (NASDAQ:MRNA) by 76.7% during the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 3,509 shares of the company’s stock after selling 11,567 shares during the period. Summit Investment Advisors Inc.’s holdings in Moderna were worth $146,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. Wilmington Savings Fund Society FSB lifted its stake in shares of Moderna by 295.0% during the 4th quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company’s stock worth $33,000 after purchasing an additional 587 shares during the period. Venturi Wealth Management LLC increased its stake in Moderna by 286.2% in the fourth quarter. Venturi Wealth Management LLC now owns 896 shares of the company’s stock valued at $37,000 after purchasing an additional 664 shares during the last quarter. Compass Planning Associates Inc acquired a new stake in Moderna in the 4th quarter worth about $37,000. Crowley Wealth Management Inc. purchased a new stake in Moderna in the 4th quarter valued at about $41,000. Finally, MassMutual Private Wealth & Trust FSB grew its holdings in Moderna by 58.2% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 1,057 shares of the company’s stock valued at $44,000 after buying an additional 389 shares during the period. Institutional investors and hedge funds own 75.33% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on MRNA. Morgan Stanley cut their price objective on shares of Moderna from $39.00 to $32.00 and set an “equal weight” rating on the stock in a report on Wednesday, April 9th. Evercore ISI set a $50.00 price target on shares of Moderna in a report on Friday, February 14th. UBS Group dropped their price objective on Moderna from $96.00 to $78.00 and set a “buy” rating for the company in a report on Wednesday, February 19th. Barclays cut Moderna from an “overweight” rating to an “equal weight” rating and reduced their target price for the company from $111.00 to $45.00 in a report on Tuesday, February 18th. Finally, Royal Bank of Canada restated a “sector perform” rating and set a $40.00 price target on shares of Moderna in a research note on Tuesday, February 18th. Four investment analysts have rated the stock with a sell rating, sixteen have issued a hold rating, three have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Moderna presently has a consensus rating of “Hold” and an average target price of $58.70.

Moderna Price Performance

NASDAQ:MRNA opened at $25.74 on Wednesday. The firm has a 50-day moving average of $30.61 and a two-hundred day moving average of $39.16. The stock has a market cap of $9.95 billion, a P/E ratio of -2.77 and a beta of 2.23. Moderna, Inc. has a 1-year low of $23.15 and a 1-year high of $170.47.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.